BIOALLIANCE-PHARMA

Regulatory News:

In continuation of their joint company announcement of July 23, 2014, BioAlliance Pharma SA (Paris:BIO) (Euronext Paris – BIO), an innovative company specialized in the development of drugs in orphan oncology diseases newly renamed Onxeo, and Topotarget A/S (NASDAQ OMX Copenhagen – TOPO), today announce that NASDAQ OMX Copenhagen has approved Onxeo’s admission to secondary trading and official listing on NASDAQ OMX Copenhagen to be effective as of August 1, 2014. From this date, BioAlliance Pharma as the continuing entity after the merger will also officially operate under the name Onxeo.

“We are very happy and proud of this final step marking the starting point for our new identity. Onxeo’s teams are ready and determined to unleash their synergistic potential to shape a dynamic player in the orphan oncology market”, declares Judith Greciet, Chief Executive Officer of Onxeo.

“With the combination of team’s expertise and a robust and innovative pipeline, Onxeo has solid basis to successfully conduct its mission to develop innovative drugs and provide patients with hope and significantly improve their lives”, declares Anders Vadsholt, Chief Executive Officer of Topotarget.

For more information on Onxeo reference is made to the admission prospectus of May 26, 2014 prepared by Onxeo and the company announcements issued by Onxeo, which are available on Onxeo’s website (www.bioalliancepharma.com ). There has been no adverse material change in Onxeo compared with the information provided in the admission prospectus dated May 26, 2014.

BioAlliance Pharma’s shares (including the newly issued shares) will remain admitted to trading on Euronext Paris under the name Onxeo (ticker: ONXEO).

The exchange of the Topotarget A/S shares against Onxeo's new ordinary shares in accordance with the merger plan is expected to occur on August 5, 2014.

Timetable:

Event		Expected Date
Issuance of legality certificate by French authority		July 22, 2014
Registration by the Danish Business Authority of completion of the merger and deregistration of Topotarget A/S		July 28, 2014
Last day of trading of Topotarget A/S on NASDAQ OMX Copenhagen		July 31, 2014
Admission to trading of Onxeo's new ordinary shares on Euronext Paris		August 1, 2014
Name change to Onxeo effective on Euronext Paris		August 1, 2014
First day of trading of Onxeo SA on NASDAQ OMX Copenhagen in ISIN FR0010095596 (ticker: ONXEO)		August 1, 2014
Exchange of Topotarget shares with new ordinary shares in Onxeo SA through VP Securities (end of day) in accordance with the exchange ratio defined in the merger plan (2 Onxeo shares for each set of 27 Topotarget shares)		August 5, 2014
Settlement of payment for fractional entitlements		August 6, 2014

About BioAlliance Pharma
Dedicated to cancer treatments with a focus on resistance targeting and orphan products, BioAlliance Pharma conceives and develops innovative products for orphan or rare diseases.
Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs. The company’s teams have the key competencies required to identify, develop and register drugs in Europe and the USA.
For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com

About Topotarget
Topotarget (NASDAQ OMX: TOPO) is a Danish-based biopharmaceutical company headquartered in Copenhagen, Denmark, dedicated to clinical development and registration of oncology products. In collaboration with Spectrum Pharmaceuticals, Inc., Topotarget focuses on the development of its lead drug candidate, belinostat, which has shown positive results in the treatment of hematological malignancies and solid tumors, obtained by both mono- and combination therapy.
For more information, please refer to www.topotarget.com .

About Onxeo
Onxeo will aim at becoming a global leader on the fast-growing market of orphan oncology drugs. It will hold a complementary portfolio of advanced programs targeting severe pathologies for which there is an unmet medical need. Onxeo will offer reinforced market attractiveness, notably towards specialized international investors, through a more important critical mass, a European scale, and a portfolio of high value-added products.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2013 Reference Document filed with the AMF on April 7, 2014, which is available on the AMF website ( http://www.amf-france.org ) or on BioAlliance Pharma SA's website ( www.bioalliancepharma.com ).

Contact:

BioAlliance Pharma:
Judith Greciet, +33 1 45 58 76 00
Chief Executive Officer
Nicolas Fellmann, +33 1 45 58 76 00
Chief Financial Officer
or
AlizéeRP:
Caroline Carmagnol, +33 6 64 18 99 59
or
Topotarget:
Bo Jesper Hansen, +45 26 12 83 84
Executive Chairman of the Board
Anders Vadsholt, +45 28 98 90 55
Chief Executive Officer
or
Impact Communications:
Michael Steen-Knudsen, +45 25 17 18 15